Literature DB >> 15380358

Acute hepatotoxicity of oncolytic adenoviruses in mouse models is associated with expression of wild-type E1a and induction of TNF-alpha.

Heidrun Engler1, Todd Machemer, Jennifer Philopena, Shu-Fen Wen, Erlinda Quijano, Murali Ramachandra, Van Tsai, Robert Ralston.   

Abstract

Replication competent adenoviruses with various E1 modifications designed to restrict their replication to tumor cells are being evaluated as oncolytic agents in clinical trials. In mouse models, we observed that such oncolytic adenoviruses showed greater hepatotoxicity than E1-deleted adenovirus vectors following intravenous administration. Additional studies in congenic BALB/c, nude, and beige/Scid mice demonstrated dose-dependent hepatotoxicity and indicated that beige/Scid was the most sensitive strain. Comparison of E1-containing viruses showed that hepatotoxicity correlated with expression of wild-type E1a in the liver. Pharmacokinetic analysis showed rapid increases in viral DNA levels in the liver with a virus containing wild-type E1a. This was correlated with rapid induction of TNF-alpha to high levels and with rapid elevation of serum ALT. Hepatotoxicity was significantly reduced for an adenovirus with deletions in the region E1a (dl01/07) or a virus lacking E1a. The results suggest a mechanism for hepatotoxicity involving virus-induced production of local TNF-alpha release and E1a-mediated sensitization of hepatocyte killing. Copyright 2004 Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15380358     DOI: 10.1016/j.virol.2004.06.043

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  21 in total

1.  Pharmacological Inhibition of β3 Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity.

Authors:  Ashley Browne; Laura A Tookman; Carin K Ingemarsdotter; Russell D Bouwman; Katrina Pirlo; Yaohe Wang; Iain A McNeish; Michelle Lockley
Journal:  Cancer Res       Date:  2015-05-14       Impact factor: 12.701

2.  Implications of the innate immune response to adenovirus and adenoviral vectors.

Authors:  Seth M Gregory; Shoab A Nazir; Jordan P Metcalf
Journal:  Future Virol       Date:  2011-03       Impact factor: 1.831

3.  Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice.

Authors:  Fang Wang; Zhiping Wang; Hongwei Tian; Meijiao Qi; Zhenxing Zhai; Shuwen Li; Renju Li; Hongjuan Zhang; Wenyun Wang; Shenjun Fu; Jianzhong Lu; Ronald Rodriguez; Yinglu Guo; Liqun Zhou
Journal:  Curr Gene Ther       Date:  2012-04-01       Impact factor: 4.391

4.  The Inflammatory and Fibrotic Patterns of Hepatic Stellate Cells Following Coagulation Factors (VII or X)-Shielded Adenovirus Infection.

Authors:  Alireza Shiri; Jamal Sarvari; Saeed Firoozi Ghahestani; Nasser Gholijani; Ali Mohammad Tamaddon; Mahroo Rastegari; Afagh Moattari; Seyed Younes Hosseini
Journal:  Curr Microbiol       Date:  2021-01-07       Impact factor: 2.188

5.  Mouse adenovirus type 1 infection in SCID mice: an experimental model for antiviral therapy of systemic adenovirus infections.

Authors:  L Lenaerts; E Verbeken; E De Clercq; L Naesens
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

6.  Ad5/48 hexon oncolytic virus expressing sTGFβRIIFc produces reduced hepatic and systemic toxicities and inhibits prostate cancer bone metastases.

Authors:  Weidong Xu; Zhenwei Zhang; Yuefeng Yang; Zebin Hu; Chi-Hsiung Wang; Melanie Morgan; Ying Wu; Ryan Hutten; Xianghui Xiao; Stuart Stock; Theresa Guise; Bellur S Prabhakar; Charles Brendler; Prem Seth
Journal:  Mol Ther       Date:  2014-05-05       Impact factor: 11.454

7.  Oncolytic adenovirus expressing soluble TGFβ receptor II-Fc-mediated inhibition of established bone metastases: a safe and effective systemic therapeutic approach for breast cancer.

Authors:  Zebin Hu; Helen Gerseny; Zhenwei Zhang; Yun-Ju Chen; Arthur Berg; Zhiling Zhang; Stuart Stock; Prem Seth
Journal:  Mol Ther       Date:  2011-06-28       Impact factor: 11.454

8.  Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS.

Authors:  Lianwen Zhang; Michael B Steele; Nathan Jenks; Jacquelyn Grell; Lukkana Suksanpaisan; Shruthi Naik; Mark J Federspiel; Martha Q Lacy; Stephen J Russell; Kah-Whye Peng
Journal:  Hum Gene Ther Clin Dev       Date:  2016-09       Impact factor: 5.032

9.  Inhibition of the inflammatory cytokine TNF-α increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression.

Authors:  Michael A Salako; Hagen Kulbe; Carin K Ingemarsdotter; Katrina J Pirlo; Sarah L Williams; Michelle Lockley; Frances R Balkwill; Iain A McNeish
Journal:  Mol Ther       Date:  2010-11-16       Impact factor: 11.454

10.  Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo.

Authors:  Pratik Singh; Duane Prasuhn; Robert M Yeh; Giuseppe Destito; Chris S Rae; Kent Osborn; M G Finn; Marianne Manchester
Journal:  J Control Release       Date:  2007-04-13       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.